Page last updated: 2024-12-05

1H-indazol-3-amine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1H-indazol-3-amine is a heterocyclic compound that has been studied for its potential therapeutic applications. It has been shown to exhibit a range of pharmacological activities, including anti-inflammatory, anti-cancer, and antimicrobial effects. Synthesis of this compound typically involves the reaction of aniline with a suitable diazonium salt, followed by cyclization. Its biological activity is attributed to its ability to interact with various biological targets, such as enzymes and receptors. The compound has been shown to inhibit the production of pro-inflammatory cytokines, and its anti-cancer activity has been linked to its ability to induce apoptosis in cancer cells. The research into 1H-indazol-3-amine is driven by the potential to develop new and effective treatments for a variety of diseases.'

1H-indazol-3-amine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13399
CHEMBL ID1331627
CHEBI ID104899
SCHEMBL ID18878
SCHEMBL ID5299723
SCHEMBL ID14041182

Synonyms (71)

Synonym
3-aminoindazole
nsc-44677
3-indazolamine
1h-indazole, 3-amino-
OPREA1_470192
HMS2604G05
NSC44677 ,
NCI60_004031
nsc-348887
nsc348887
1h-indazol-3-amine
1h-indazol-3-ylamine
AE-413/25046004
874-05-5
1,2-dihydro-3h-indazol-3-imine
NCGC00013536
smr000353333
MLS001001985
NCI44677
NCISTRUC1_001630
NCISTRUC2_000161
NCGC00096649-01
CHEBI:104899
AKOS000115531
CHEMBL1331627 ,
jnz ,
bdbm50339013
aminoindazole
amino-indazole
3-amino-1h-indazole
nsc 44677
EN300-02352
AKOS006222497
1h-indazole-3-ylamine
2h-indazol-3-amine
54107-84-5
CCG-37665
NCGC00013536-02
BP-10432
FT-0647301
FT-0604095
MB69235
indazol-3-amine
10P-212
AM20060880
AR2288
indazole amine
3-amino benzpyrazole
SCHEMBL18878
SCHEMBL5299723
3NUS
SY007051
STL414950
mfcd00182045
J-504673
DTXSID5061243
SCHEMBL14041182
Q27182567
1h-indazol-3-amine, aldrichcpr
CS-W002482
Z56820416
BBL104359
FT-0729924
BCP27432
10.14272/YDTDKKULPWTHRV-UHFFFAOYSA-N.1
doi:10.14272/ydtdkkulpwthrv-uhfffaoysa-n.1
CCG-302505
SB39259
bdbm604504
us11661426, compound 353a
1h-indazol-3-amine, monohydrochloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
GLS proteinHomo sapiens (human)Potency11.22020.35487.935539.8107AID624170
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency3.54810.036619.637650.1187AID2100
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency3.98110.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)IC50 (µMol)311.00000.00251.45139.0000AID580957
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
type B pancreatic cell development3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
hyperosmotic response3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
epidermal growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phospholipase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
calcium-mediated signaling3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
actin cytoskeleton organization3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
T cell costimulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
activation of protein kinase B activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to insulin stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of toll-like receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of canonical NF-kappaB signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of mast cell degranulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein autophosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to epidermal growth factor stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of protein localization to plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of sprouting angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of endothelial cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
3-phosphoinositide-dependent protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
ATP binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase activator activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein serine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nucleus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasm3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
focal adhesion3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
postsynaptic density3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasmic vesicle3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell projection3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID613145Inhibition of JNK1 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613158Inhibition of GSK3-beta expressed in Escherichia coli or baculovirus-infected insect cells using ATP as substrate at 667 uM by fluorescence polarization assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613172Inhibition of SGK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613157Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613169Inhibition of PIM1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613144Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613168Inhibition of PI3Kdelta expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613170Inhibition of RIP2 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by fluorescence polarization assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613159Inhibition of IGF1R expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613155Inhibition of ErbB2 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613162Inhibition of MK2 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613147Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613165Inhibition of PAK2 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613143Inhibition of IKK-beta expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613160Inhibition of ITK expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613156Inhibition of ErbB4 expressed in Escherichia coli or baculovirus-infected insect cells at 400 to 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613150Inhibition of AurA expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613151Inhibition of AurB expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613149Inhibition of ASK1 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613164Inhibition of PAK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613171Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613148Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613152Inhibition of B-Raf expressed in Escherichia coli or baculovirus-infected insect cells using ATP as substrate at 400 uM by fluorescence polarization assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613153Inhibition of EGFR expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613161Inhibition of JAK3 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613163Inhibition of p38alpha expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613166Inhibition of PDK1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613173Inhibition of SYK expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613167Inhibition of PI3Kalpha expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613154Inhibition of FES expressed in Escherichia coli or baculovirus-infected insect cells using ATP as substrate at 400 uM by fluorescence polarization assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID580957Inhibition of His-tagged-truncated human PDK1 preincubated with substrate biotinylated-AKT3 for 30 mins measured after 3 hrs by Scintillation proximity assay2010ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's9 (75.00)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.01 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]